Versantis receives U.S. FDA orphan drug designation for VS-01

Latest pharma news updates

Versantis AG, a clinical-stage company developing novel therapies for rare liver diseases and rare pediatric diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead product candidate VS-01 for the treatment of hyperammonemia (HA) in inborn errors of metabolism (IEM).

 “This orphan drug designation from the FDA validates the scientific rationale of VS-01 in a new indication encompassing multiple genetic disorders where there is a vital need to remove the life-threatening build-up of ammonia,” said Meriam Kabbaj, Chief Operations Officer and Co-founder of Versantis. “VS-01 has now received U.S. FDA ODD for two main indications, hyperammonemia in inborn errors of metabolism and Acute-on-chronic Liver Failure (ACLF). Orphan drug incentives considerably strengthen the clinical development plan of our liposomal scavenging platform technology and provide a huge opportunity to soon address the growing burden of metabolic / liver diseases.”

The U.S. FDA ODD program is designed to provide incentives to sponsors developing drugs and biologics for rare diseases and conditions, in part defined as affecting fewer than 200,000 people in the United States. Sponsors of designated orphan drugs are eligible for tax credits for clinical trial costs, waiver of the user fee for marketing applications and, upon approval, consideration for seven years of marketing exclusivity.

“VS-01 is potentially a game-changing medication for the treatment of acute hyperammonemia in an emergency setting. The new designation from the FDA continues to validate our approach and development of VS-01, which was shown to be safe and well-tolerated in our Phase 1b clinical study in patients with decompensated liver cirrhosis,” said Vincent Forster, Versantis’ Co-founder and CEO. “Building on this encouraging first experience in patients, we are in the process of raising new funds to continue advancing VS-01 towards its much-needed use in clinical practice.”

Tags : #Versantis #FDA #FDANews #VS01 #LiverFailure

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Deadly 17: WHO’s Vaccine Priority List to Tackle Life-Threatening InfectionsNovember 09, 2024
Is Your Gut Telling You Something? The Bacterial Clues to Early Rheumatoid ArthritisNovember 09, 2024
Newcastle University Announces VC Excellence Scholarships for Undergraduate and Postgraduate StudiesNovember 08, 2024
Beyond the X-ray: Celebrating the Pioneers of Radiography on World Radiography DayNovember 08, 2024
Digital Doctors and Village Heroes: Tackling Depression and Stigma in India’s HeartlandNovember 08, 2024
Why Are Food Giants Pushing ‘Low-Star’ Nutrition on Low-Income Countries?November 08, 2024
NokAir joins hands with Çelebi for world class ground handling services for newly launched Bangkok-Mumbai routeNovember 07, 2024
Why Are Rare Disease Patients Paying a Fortune When Local Production Could Save Lives?November 07, 2024
Building Lips in the Lab: How Scientists Are Growing Lab Lips to Heal and RebuildNovember 07, 2024
National Cancer Awareness Day: How Small Changes Today Can Save Lives TomorrowNovember 07, 2024
Introducing an AI tool for accurate diagnosis of cholelithiasis on abdominal CT scansNovember 06, 2024
Nat Habit Unveils New Chapter of “Breathe Life Into Your Beauty” Campaign championed by Content Creators and the Launch of VeDHA, digital skin analysis toolNovember 06, 2024
High Level of Pollution Spikes Cardio and Respiratory Problems; Experts Call for Urgent Attention and Action to Mitigate the Risks November 06, 2024
HR leaders ready to shape India's future workforce - XLRI and Leadup Universe seminar in PuneNovember 05, 2024
Nestlé India and SM Sehgal Foundation celebrate 5 years of Project Vriddhi November 05, 2024
Why Tuberculosis Is Still the World’s Leading Killer in 2024 And How We’re Failing to Stop ItNovember 05, 2024
Crompton Launches the Nigella Pro Mixer Grinder to Revolutionize Kitchen ConvenienceNovember 05, 2024
Invisible Shadows: The Growing Crisis of Corneal Blindness in IndiaNovember 05, 2024
Thai AirAsia Entrusts Çelebi India with Ground Handling for New Hyderabad- Bangkok Flights, Signalling Further India Expansion November 05, 2024
Thai AirAsia Entrusts Çelebi India with Ground Handling for New Hyderabad- Bangkok Flights, Signalling Further India Expansion November 05, 2024